Monitoring effects of alpha-human atrial natriuretic polypeptide (alpha-hANP) on left ventricular function in patients with essential hypertension with a cardiac probe.
The effects of alpha-hANP on left ventricular function were studied with a cardiac probe in ten patients with essential hypertension. Our data showed that intravenous administration of alpha-hANP significantly elevated left ventricular function. At 5 min, the elevation of EF, RCO, ER, RSV, PFR were 13.23% (P less than 0.02), 12.7 (P less than 0.02), 0.618 (P less than 0.02), 0.133 (P less than 0.05), 0.283 (P less than 0.01), respectively. At 10 min, the increase of EF, ER, were 11.07% (P less than 0.02) and 0.233 (P less than 0.01), respectively. Atriopeptin significantly reduced systolic and diastolic blood pressure from 2 min to 20 min (P less than 0.001-0.05).
D000328:Adult; D000368:Aged; D009320:Atrial Natriuretic Factor / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects*; D002302:Cardiac Output / Q000187:drug effects*; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009200:Myocardial Contraction / Q000187:drug effects*
D009320:Atrial Natriuretic Factor